Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants

Emerging SARS-CoV-2 variants have accrued mutations within the spike protein rendering most therapeutic monoclonal antibodies against COVID-19 ineffective. Hence there is an unmet need for broad-spectrum mAb treatments for COVID-19 that are more resistant to antigenically drifted SARS-CoV-2 variants...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Wenjuan Du, Rick Janssens, Anna Z. Mykytyn, Wentao Li, Dubravka Drabek, Rien van Haperen, Marianthi Chatziandreou, Melanie Rissmann, Joline van der Lee, Melissa van Dortmondt, Itziar Serna Martin, Frank J. M. van Kuppeveld, Daniel L. Hurdiss, Bart L. Haagmans, Frank Grosveld, Berend-Jan Bosch
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2023-02-01
Edice:	Frontiers in Immunology
Témata:	heavy-chain-only antibody avidity SARS-CoV-2 antibody-mediated neutralization neutralization escape
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1111385/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!